Navigation Links
Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol
Date:4/26/2010

p drugs to attack previously inaccessible clinical pathways. The most important features of LNA-based drugs include excellent specificity, providing optimal targeting; increased affinity to targets providing improved potency, and strong pharmacology upon systemic delivery without complicated delivery vehicles.

About Santaris Pharma A/S

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the Company's proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The Company's research and development activities focus on infectious diseases and metabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, infectious and inflammatory diseases, and rare genetic disorders. The Company has strategic partnerships with Enzon Pharmaceuticals, GlaxoSmithKline, Pfizer and Shire plc. As part of its broad patent estate, the Company holds exclusive worldwide rights to all therapeutic uses of LNAs. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States. Please visit www.santaris.com for more information.

(1) World Health Organization -

SOURCE Santaris Pharma A/S
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
3. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
4. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
5. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
6. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
7. New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US Operations
8. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
9. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market by ... Systems, Table-top Counters) by End-user (Inpatient Pharmacy Automation, ... to 2019” analyzes and studies the major market ... Asia-Pacific, and the Rest of the World (RoW). ... spread through 300 pages and in-depth TOC on ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Convey ... that a team from Iowa State University won first ... contest. Using a Convey HC-2ex, the team’s solution achieved ... times faster than the second place finisher. , Experts ... embarked upon the month long challenge, using a variety ...
(Date:10/20/2014)... ON , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: ... $1.7 million which brings Q3 orders to $5.8 million and provides ... control projects in North America and one ... continue to bid new projects at record levels," said Peter ... were higher at the end of Q3 than they have been ...
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... P. Horovitz , Ph.D., from its board of directors effective ... in August 2003, and served as its chairman from June ... on the Nominating and Corporate Governance and Audit Committees of ... more than a decade of dedicated service to GenVec, and ...
Breaking Biology Technology:Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2
... April 9, 2012 The University of Southern California Marshall ... announced its 6th Annual Marshall School of Business Leadership ... 11:00 am to 5:30 pm, at Los Angeles, newest landmark, ... (Logo: http://photos.prnewswire.com/prnh/20120409/LA84249LOGO ) A new dynamic ...
... WALTHAM, Mass., April 9, 2012   Syndax Pharmaceuticals, ... that investigators at The University of Texas MD ... have initiated a phase 1/2 study combining Syndax,s ... patients with locally recurrent or distant relapsed metastatic ...
... Carbon Limited today announces that they will be exhibiting at ... sheet of carbon just one atom thick, has been described ... University in 2004, for which the team was awarded a ... commercially. To support this work the UK Government recently ...
Cached Biology Technology:USC Marshall School of Business 6th Annual Leadership Summit 2USC Marshall School of Business 6th Annual Leadership Summit 3Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer 2Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer 3UK company to demonstrate their commercially effective graphene production process 2
(Date:10/15/2014)... and to an unexpected extent. The outbreak does not ... virus shows a new disease dynamic in regions, where ... the German National Academy of Sciences Leopoldina, acatech – ... Union of the German Academies of Sciences and Humanities ... , In the statement the academies call for the ...
(Date:10/15/2014)... Rosenstiel Award for Distinguished Work in Biomedical Science by ... of genomic instability and its implications for the immune ... to win the Rosenstiel Award; the first, Rod McKinnon, ... the Charles A. Janeway Professor of Pediatrics and Professor ... at the Howard Hughes Medical Institute at Boston Children,s ...
(Date:10/14/2014)... published in Cancer Research shows SIRT6—a protein ... cancers—can promote the development of skin cancers by turning ... of sun-damaged skin cells. , Previously considered protective, SIRT6 ... sirtuins that help regulate genomic stability and prevent some ... repair DNA damage, which can lead to cancer. This ...
Breaking Biology News(10 mins):Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
... OAK RIDGE, Tenn., Jan. 17, 2008 -- Oak ... work for the automotive supplier industry initiated through ... Technologies, or USAutoPARTs collaborative announced today at the ... Made up of a consortium of federal and ...
... Troy, N.Y. - Two theoretical physicists at Rensselaer ... the long-sought-after pathway that an HIV peptide takes ... years of biocomputation and simulation to uncover a ... penetrates the cell membrane. The discovery could help ...
... federal fishery agencies, regional management councils, universities, conservation groups, ... the Cocoanut Grove conference center in Santa Cruz, Calif., ... Groundfish Conference. The Western Groundfish Conference is ... Mary Yoklavich, research biologist with NOAA Fisheries Service. It ...
Cached Biology News:Oak Ridge to lead auto supplier R&D partnership 2Oak Ridge to lead auto supplier R&D partnership 3Researchers reveal HIV peptide's possible pathway into the cell 2Researchers reveal HIV peptide's possible pathway into the cell 3
muscle actin (HUC1-1)...
Anti-Mouse MIP-1g, Biotin (Polyclonal) (rabbit IgG)...
... Anti-NY-ESO-1, clone E978 ... NM_001327 Immunogen : ... Formulation: mouse ascites with ... Assurance: routinely evaluated by ...
... Chicken polyclonal to Opsin 1 ( Abpromise ... Antigen: Synthetic peptide: YEDSTHASIFTYT, corresponding to amino ... and synthetic peptide corresponding to amino acids 18/30 ... and used as immunogen. Entrez ...
Biology Products: